{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T23:36:46Z","timestamp":1790897806699,"version":"4.1.0"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003970","name":"Isfahan University of Medical Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003970","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.msard.2025.106590","type":"journal-article","created":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T02:49:06Z","timestamp":1750128546000},"page":"106590","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Efficacy of fingolimod in multiple sclerosis patients with spinal cord involvement: an open-label study"],"prefix":"10.1016","volume":"101","author":[{"given":"Fereshteh","family":"Ashtari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Pirmoradian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aryan","family":"Kavosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sina","family":"Arabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"1","given":"Iman","family":"Adibi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Awat","family":"Feizi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arshia","family":"Ghalamkari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.msard.2025.106590_bib0002","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1002\/ana.26281","article-title":"Spinal cord atrophy predicts progressive disease in relapsing multiple sclerosis","volume":"91","author":"Bischof","year":"2022","journal-title":"Ann. Neurol."},{"issue":"2","key":"10.1016\/j.msard.2025.106590_bib0003","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1212\/WNL.62.2.226","article-title":"Spinal cord abnormalities in recently diagnosed MS patients: added value of spinal MRI examination","volume":"62","author":"Bot","year":"2004","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.msard.2025.106590_bib0004","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000209444","article-title":"Using the progression independent of relapse activity framework to unveil the pathobiological foundations of multiple sclerosis","volume":"103","author":"Ciccarelli","year":"2024","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.msard.2025.106590_bib0005","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1056\/NEJMoa0907839","article-title":"Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis","volume":"362","author":"Cohen","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.msard.2025.106590_bib0006","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1007\/s00415-017-8642-5","article-title":"Efficacy of fingolimod and interferon beta-1b on cognitive, MRI, and clinical outcomes in relapsing-remitting multiple sclerosis: an 18-month, open-label, rater-blinded, randomised, multicentre study (the GOLDEN study)","volume":"264","author":"Comi","year":"2017","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2025.106590_bib0007","doi-asserted-by":"crossref","DOI":"10.1177\/1756286418774338","article-title":"Phase IV study of retention on fingolimod versus injectable multiple sclerosis therapies: a randomized clinical trial","volume":"11","author":"Cree","year":"2018","journal-title":"Ther. Adv. Neurol. Disord."},{"issue":"6","key":"10.1016\/j.msard.2025.106590_bib0008","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1007\/s11940-015-0354-5","article-title":"The transition from first-line to second-line therapy in multiple sclerosis","volume":"17","author":"D\u00f6rr","year":"2015","journal-title":"Curr. Treat. Options. Neurol."},{"issue":"1","key":"10.1016\/j.msard.2025.106590_bib0009","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s12880-016-0158-4","article-title":"The effect of intramuscular interferon beta-1a on spinal cord volume in relapsing-remitting multiple sclerosis","volume":"16","author":"Dupuy","year":"2016","journal-title":"BMC. Med. ImAging"},{"key":"10.1016\/j.msard.2025.106590_bib0010","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.msard.2018.09.008","article-title":"Adverse psychiatric effects of disease-modifying therapies in multiple sclerosis: a systematic review","volume":"26","author":"Gasim","year":"2018","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2025.106590_bib0001","unstructured":"Guidelines and Therapeutic Protocols Tehran University of Medical Sciences [Available from: https:\/\/treatment.tums.ac.ir\/%D8%A7%D8%B3%D8%AA%D8%A7%D9%86%D8%AF%D8%A7%D8%B1%D8%AF%D9%87%D8%A7%E2%80%93%DA%AF%D8%A7%DB%8C%D8%AF%D9%84%D8%A7%DB%8C%D9%86-%D9%87%D8%A7-%D9%88-%D9%BE%D8%B1%D9%88%D8%AA%DA%A9%D9%84-%D9%87%D8%A7%DB%8C-%D8%AF%D8%B1%D9%85%D8%A7%D9%86%DB%8C."},{"issue":"12","key":"10.1016\/j.msard.2025.106590_bib0011","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1016\/j.amjmed.2020.05.049","article-title":"Treatment of Multiple sclerosis: a review","volume":"133","author":"Hauser","year":"2020","journal-title":"Am. J. Med."},{"issue":"5","key":"10.1016\/j.msard.2025.106590_bib0012","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1056\/NEJMoa0909494","article-title":"A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis","volume":"362","author":"Kappos","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.msard.2025.106590_bib0013","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/nrneurol.2015.80","article-title":"Spinal cord MRI in multiple sclerosis\u2013diagnostic, prognostic and clinical value","volume":"11","author":"Kearney","year":"2015","journal-title":"Nat. Rev. Neurol."},{"issue":"2","key":"10.1016\/j.msard.2025.106590_bib0014","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1177\/1756285616628766","article-title":"Fingolimod in the treatment of relapsing-remitting multiple sclerosis: long-term experience and an update on the clinical evidence","volume":"9","author":"Khatri","year":"2016","journal-title":"Ther. Adv. Neurol. Disord."},{"issue":"1","key":"10.1016\/j.msard.2025.106590_bib0015","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3988\/jcn.2015.11.1.9","article-title":"Oral disease-modifying therapies for multiple sclerosis","volume":"11","author":"Kim","year":"2015","journal-title":"J. Clin. Neurol."},{"key":"10.1016\/j.msard.2025.106590_bib0016","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2023.104994","article-title":"Effect of disease-modifying treatment on spinal cord lesion formation in multiple sclerosis: a retrospective observational study","volume":"79","author":"Kreiter","year":"2023","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"11","key":"10.1016\/j.msard.2025.106590_bib0017","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1212\/WNL.33.11.1444","article-title":"Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS)","volume":"33","author":"Kurtzke","year":"1983","journal-title":"Neurology"},{"issue":"8","key":"10.1016\/j.msard.2025.106590_bib0018","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1136\/jnnp.74.8.1090","article-title":"Spinal cord atrophy and disability in multiple sclerosis over four years: application of a reproducible automated technique in monitoring disease progression in a cohort of the interferon beta-1a (Rebif) treatment trial","volume":"74","author":"Lin","year":"2003","journal-title":"J. Neurol. Neurosurg. Psychiatr"},{"issue":"4","key":"10.1016\/j.msard.2025.106590_bib0019","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1177\/13524585211031128","article-title":"Risk of depression in multiple sclerosis across disease-modifying therapies","volume":"28","author":"Longinetti","year":"2022","journal-title":"Mult. Scler."},{"issue":"16","key":"10.1016\/j.msard.2025.106590_bib0020","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1212\/01.wnl.0000327609.57688.ea","article-title":"FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis","volume":"71","author":"Mehling","year":"2008","journal-title":"Neurology"},{"issue":"12","key":"10.1016\/j.msard.2025.106590_bib0021","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/sj.sc.3101798","article-title":"Clinical characteristics, course and prognosis of spinal multiple sclerosis","volume":"43","author":"Nociti","year":"2005","journal-title":"Spinal Cord."},{"issue":"1","key":"10.1016\/j.msard.2025.106590_bib0022","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1212\/01.wnl.0000338569.32367.3d","article-title":"Oral fingolimod (FTY720) in multiple sclerosis: two-year results of a phase II extension study","volume":"72","author":"O'Connor","year":"2009","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.msard.2025.106590_bib0023","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1136\/jnnp.64.3.353","article-title":"Asymptomatic spinal cord lesions in clinically isolated optic nerve, brain stem, and spinal cord syndromes suggestive of demyelination","volume":"64","author":"O'Riordan","year":"1998","journal-title":"J. Neurol. Neurosurg. Psychiatr"},{"issue":"3","key":"10.1016\/j.msard.2025.106590_bib0024","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10030463","article-title":"Recurrence and prognostic value of asymptomatic spinal cord lesions in multiple sclerosis","volume":"10","author":"Ostini","year":"2021","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.msard.2025.106590_bib0025","series-title":"Proceedings of the BCTRIMS 24th Annual Meeting","article-title":"Weight loss in multiple sclerosis therapy: a rare adverse effect of fingolimod","author":"Pinto","year":"2023"},{"issue":"2","key":"10.1016\/j.msard.2025.106590_bib0026","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/ana.22366","article-title":"Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria","volume":"69","author":"Polman","year":"2011","journal-title":"Ann. Neurol."},{"issue":"17","key":"10.1016\/j.msard.2025.106590_bib0027","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1212\/WNL.0000000000005347","article-title":"Practice guideline recommendations summary: disease-modifying therapies for adults with multiple sclerosis: report of the guideline development, dissemination, and implementation Subcommittee of the American academy of neurology","volume":"90","author":"Rae-Grant","year":"2018","journal-title":"Neurology."},{"issue":"6","key":"10.1016\/j.msard.2025.106590_bib0028","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1177\/1352458513508835","article-title":"A randomized clinical trial of oral versus intravenous methylprednisolone for relapse of MS","volume":"20","author":"Ramo-Tello","year":"2014","journal-title":"Mult. Scler."},{"issue":"2","key":"10.1016\/j.msard.2025.106590_bib0029","first-page":"321","article-title":"CNS inflammatory demyelinating disorders: MS, NMOSD and MOG antibody associated disease","volume":"68","author":"Rosenthal","year":"2020","journal-title":"Off. Publ. Am. Fed. Clin. Res."},{"issue":"8","key":"10.1016\/j.msard.2025.106590_bib0030","doi-asserted-by":"crossref","first-page":"673","DOI":"10.2165\/11207350-000000000-00000","article-title":"Fingolimod: a review of its use in the management of relapsing-remitting multiple sclerosis","volume":"25","author":"Scott","year":"2011","journal-title":"CNS. Drugs"},{"key":"10.1016\/j.msard.2025.106590_bib0031","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1146\/annurev-immunol-032713-120227","article-title":"Immunology of relapse and remission in multiple sclerosis","volume":"32","author":"Steinman","year":"2014","journal-title":"Annu. Rev. Immunol."},{"issue":"2","key":"10.1016\/j.msard.2025.106590_bib0032","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria","volume":"17","author":"Thompson","year":"2018","journal-title":"Lancet Neurol."},{"issue":"4","key":"10.1016\/j.msard.2025.106590_bib0033","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1111\/bcp.14198","article-title":"The efficacy and safety of fingolimod in patients with relapsing multiple sclerosis: a meta-analysis","volume":"86","author":"Yang","year":"2020","journal-title":"Br. J. Clin. Pharmacol."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034825003323?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034825003323?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T00:42:04Z","timestamp":1755650524000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034825003323"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":33,"alternative-id":["S2211034825003323"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2025.106590","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy of fingolimod in multiple sclerosis patients with spinal cord involvement: an open-label study","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2025.106590","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"106590"}}